Maru/Matchbox has announced the appointment of Rich Durante as Managing Director of Pharmaceuticals and Medicines. Rich will be based in Boston.
Rich joins Matchbox from Kantar, where he was Managing Partner for the Brand Strategy Group (formerly MaPS). For 20+ years, Rich has conducted market research for pharmaceutical and other types of life sciences companies and, prior to that, public health research in academic settings. His research has spanned many therapeutic areas including oncology, vaccines / infectious disease, respiratory, cardiovascular, endocrinology, neurology, mental health, urology, nephrology, and rheumatology and includes patient journey studies, consumer and healthcare professional (HCP) segmentation, product/service optimization and forecasting, and HCP brand strategy research.
Additionally, Rich provides distinct thought-leadership, having published papers on novel qualitative and quantitative methodologies, unique applications of existing methodologies in the healthcare space, and general commentaries on medical practice in areas ranging from oncology to immunology.
As Managing Director of the Pharmaceuticals and Medicines sector, Rich will be responsible for one of Matchbox’s fast-growing verticals.
Ged Parton, CEO of Maru Group, said: “Rich brings with him a wealth of experience in a range of industries, but his deep sector expertise in life sciences & healthcare are what will lead our clients to make informed, impactful business decisions that move people into action. He is a real asset to the company and I am delighted to welcome him to the team.”
Rich’s arrival is the latest in a number of recent senior hires for Maru Group. “Clients across sectors are looking for insights to drive business decisions and deliver growth,” added Parton. “We are committed to investing in the right talent and proprietary technology to help our clients achieve these results. I look forward to the continued growth of our team over the coming months.”